Arix Bioscience
Sustainability Report and Carbon Intensity Rankings
Is Arix Bioscience doing their part?
Their DitchCarbon score is 58
Arix Bioscience has a DitchCarbon Score of 58 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which is a measure of how much carbon emissions are produced relative to their activities. A higher score would suggest a lower carbon intensity and a stronger commitment to reducing their environmental impact.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Arix Bioscience operates in the research and development sector, which has a very low carbon intensity ranking. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Arix Bioscience is situated in the United Kingdom, which has a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint.
Unlock 30+ emissions data points on Arix Bioscience
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Arix Bioscience
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
6.64%
...this company is doing 6.64% better in emissions than the industry average.
Arix Bioscience plc, founded in 2015, is a prominent player in the research and development sector of the global healthcare and life science industry. With its headquarters in London and an additional office in New York, the company specializes in sourcing, financing, and building businesses that focus on medical innovation. Listed on the London Stock Exchange, Arix Bioscience leverages its connections with academic science and strategic partnerships to advance healthcare solutions.
emission intelligence's platform recommendations for Arix Bioscience
Arix Bioscience should undertake a detailed inventory of all Scope 2 emissions sources, establish reduction targets tailored to each type of purchased energy, and improve their monitoring and reporting systems to better track progress and uncover additional reduction opportunities, which could potentially lower their emissions by 25%.
Bad news, Arix Bioscience hasn't committed to SBTi goals yet
Arix Bioscience has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not defined or announced clear goals for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.